Iqvia Holdings Inc.
IQVIA Holdings Inc. Announces $2 Billion Senior Notes Offering
Summary
On June 4, 2025, IQVIA Holdings Inc., through its subsidiary IQVIA Inc., completed the issuance of $2 billion in 6.250% senior notes due 2032. The net proceeds will be used to repay existing borrowings and for general corporate purposes. The notes are unsecured and will bear interest at 6.250% per year, payable semi-annually. An Indenture governing the notes is filed as Exhibit 4.1 to this 8-K report.
Profitelligence Alerts
Get alerts for IQV
Be first to know when Iqvia Holdings Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Iqvia Holdings Inc.
Iqvia Holdings Inc. is a leading global provider of advanced analytics, technology solutions, and contract research services. Its primary function is to support the healthcare sector by offering data-driven insights and innovations that underpin strategic decision-making across pharmaceutical, biotechnology, and medical device industries. Iqvia plays a crucial role in facilitating drug development through its comprehensive clinical research capabilities, encompassing everything from clinical trials to regulatory submissions. Additionally, its technology solutions leverage artificial intelligence and machine learning to optimize clinical and commercial operations, contributing to enhanced patient outcomes and streamlined healthcare delivery. Iqvia's integrated services impact sectors such as drug safety, patient engagement, and real-world evidence, making it an indispensable partner for healthcare companies seeking to navigate complex markets and regulatory environments. Globally recognized for its vast data repository and cutting-edge analytical platforms, Iqvia serves as a pivotal player in the transformation of the healthcare landscape, empowering organizations to accelerate innovation and improve patient care.
Official SEC Documents
Advertisement